Fate Therapeutics Inc (FATE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

3535 GENERAL ATOMICS COURT SAN DIEGO, CA 92121

Fate Therapeutics, Inc provides biotechnology services. The company researches and develops therapies to repair and regenerate body tissues with the help of stem cells.

Data as of 2020-06-27
Market Cap2.867 Billion Shares Outstanding84.801 Million Avg 30-day Volume1.318 Million
P/E Ratio Dividend Yield EPS-1.58
Price/Sales271.43 Price cash flow ratio Price free cash flow ratio-30.2
Book Value2.59 Price to Tangible Book13.63 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.129148
BETA1.76972 52-week High/Low37.24 / 12.59 Stddev0.210085
View SEC Filings from FATE instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 6 5 (0.33%)
13F Filers holding this stock: 159 55 (3.6%)
Aggregate 13F shares on 03/31/2020: 75.587 Million 41.731 Million
Aggregate 13F shares on 12/31/2019: 72.206 Million 39.221 Million
Percent change: 4.68% 6.40%
Funds creating new positions: 36 12
Funds Adding to an existing position: 45 15
Funds closing out their position: 25 12
Funds reducing their position: 57 21
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FATE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FATE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1.4 Million total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ENYEDY MARK J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
439,017 2020-06-30 0

RASTETTER WILLIAM H

  • Director
0 2020-06-25 2

AGARWAL SHEFALI CHIEF MEDICAL OFFICER

  • Officer
78,611 2020-06-25 3

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
1,586,174 2020-06-23 3

NASHAT AMIR

  • Director
0 2020-06-18 4

HERSHBERG ROBERT

  • Director
1,890 2020-06-15 2

MULTANI PRATIK S

  • Director
0 2020-06-11 0

EPSTEIN ROBERT S

  • Director
0 2020-06-08 1

WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT

  • Officer
16,783 2020-05-27 0

COUGHLIN TIMOTHY

  • Director
32,000 2020-05-15 1

MENDLEIN JOHN

  • Director
0 2020-05-01 1

LEE MICHAEL STEWART

  • Director
0 2020-05-01 1

JOOSS KARIN

  • Director
0 2020-05-01 1

VALAMEHR BAHRAM CHIEF DEVELOPMENT OFFICER

  • Officer
87,211 2020-02-03 3

WOLCHKO J SCOTT PRESIDENT AND CEO

  • Officer
  • Director
419,969 2020-01-30 4

SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER

  • Officer
143,091 2020-01-08 3

TAHL CINDY GENERAL COUNSEL AND SECRETARY

  • Officer
99,518 2020-01-08 2

ABBOT STEWART CHIEF DEVELOPMENT OFFICER

  • Officer
64,917 2018-05-15 0

STORGARD CHRIS CHIEF MEDICAL OFFICER

  • Officer
0 2018-01-16 0

FLYNN PETER D EVP, HEAD OF GLOBAL DEV

  • Officer
0 2017-10-13 0

FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER

  • Officer
103,816 2016-01-08 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

REDMILE GROUP, LLC - Director - > 10% Owner see footnote

GREEN JEREMY - Director - > 10% Owner see footnote

2020-06-11 P 1,412,928 $28.31 a 12,629,737 12,629,737.00 indirect
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments